SCHEMBL901540

SCHEMBL901540

c1ccc(NCC2CCCCC2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 2/20 0.57
CARM1 Q86X55 1/20 0.53
PRMT6 Q96LA8 1/20 0.53
EPHX2 P34913 1/20 0.51
APP P05067 1/20 0.50
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
SMN1; SMN2 Q16637 3/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
ALDH1A1 P00352 2/20 0.44
MAPT P10636 1/20 0.44
ALOX12 P18054 1/20 0.44
HTT P42858 1/20 0.44
KCNH3 Q9ULD8 1/20 0.44
CRHR1 P34998 1/20 0.43
UTS2R Q9UKP6 2/20 0.43
ACHE P22303 1/20 0.43
BACE1 P56817 1/20 0.43
KDM4C Q9H3R0 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL901572 1.00 EPHX1 (0.57) EPHX1CARM1PRMT6EPHX2APP
SCHEMBL22393075 1.00 EPHX1 (0.57) EPHX1CARM1PRMT6EPHX2APP
SCHEMBL23845320 1.00 EPHX1 (0.57) EPHX1CARM1PRMT6EPHX2APP
SCHEMBL9679337 0.98 EPHX1 (0.54) EPHX1CARM1PRMT6EPHX2APP
SCHEMBL872221 0.94 CARM1 (0.54) EPHX1CARM1PRMT6EPHX2APP
Hydrogen Sulfide SCHEMBL15066150 0.92 CARM1 (0.53) EPHX1CARM1PRMT6EPHX2APP
Water SCHEMBL15066370 0.92 CARM1 (0.53) EPHX1CARM1PRMT6EPHX2APP
SCHEMBL10055002 0.89 CARM1 (0.57) EPHX1CARM1PRMT6MEN1KMT2A
SCHEMBL18434523 0.89 CARM1 (0.57) EPHX1CARM1PRMT6MEN1KMT2A
SCHEMBL10055063 0.89 CARM1 (0.57) EPHX1CARM1PRMT6MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0617053-B2 Process for hydrotreating resins to lighten color EASTMAN CHEMICAL RESINS INC (US) 2005-02-09 EP claimed
EP-0617053-B1 Process for hydrotreating resins to lighten color HERCULES INC (US) 1998-10-07 EP claimed
US-20250361236-A9 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES INC (US) 2025-11-27 US disclosed
US-20240400568-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2024-12-05 US disclosed
EP-4445902-A2 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS Carna Biosciences, Inc. (JP) 2024-10-16 EP disclosed
EP-4081305-B1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS CARNA BIOSCIENCES INC (JP) 2024-09-18 EP disclosed
US-12054490-B2 Diacylglycerol kinase modulating compounds GILEAD SCIENCES, INC. (US) 2024-08-06 US disclosed
CN-118324767-A Diacylglycerol kinase modulating compounds 卡尔那生物科学株式会社 2024-07-12 CN disclosed
US-20240182476-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2024-06-06 US disclosed
CN-117946180-A Chiral iridium complex and preparation method and application thereof 南方科技大学 2024-04-30 CN disclosed
US-11845723-B2 Diacylglycerol kinase modulating compounds GILEAD SCIENCES, INC. (US) 2023-12-19 US disclosed
CN-101679596-A Super-high refractive index optical resin composition having high heat deflection temperature and excellent thermal stability, optical lens using same and method for manufacturing the optical lens SHIN DAE SPECIALTIES CO LTD 2010-03-24 CN disclosed
EP-2010528-A2 6-O-SUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF INHIBITING CSF-1R SIGNALING Novartis Pharma AG (CH) 2009-01-07 EP disclosed
WO-2007121484-A2 6-O-SUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF INHIBITING CSF-1R SIGNALING NOVARTIS AG (CH) 2007-10-25 WO disclosed
EP-1562595-A1 DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2005-08-17 EP disclosed
WO-2004026305-A1 DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONIST ELI LILLY AND COMPANY (US) 2004-04-01 WO disclosed
EP-0598962-A1 Imidazole derivatives as calcium channel blockers NEUROSEARCH A/S (DK) 1994-06-01 EP disclosed
US-5296493-A Analgesics or antiischemics NEUROSEARCH A/S (DK) 1994-03-22 US disclosed
EP-0087047-B1 PROCESS FOR THE PREPARATION OF N SUBSTITUTED URETHANES BAYER AG (DE) 1985-08-07 EP disclosed
EP-0087047-A2 Process for the preparation of N substituted urethanes BAYER AG (DE) 1983-08-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240400568-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK EPHX1 1840/4885CARM1 2598/4885PRMT6 1544/4885
US-12054490-B2 Diacylglycerol kinase modulating compounds DGKG, DGKB, DGKK EPHX1 1840/4885CARM1 2598/4885PRMT6 1544/4885
US-11845723-B2 Diacylglycerol kinase modulating compounds DGKG, DGKB, DGKK EPHX1 1840/4885CARM1 2598/4885PRMT6 1544/4885
US-20240182476-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK EPHX1 1840/4885CARM1 2598/4885PRMT6 1544/4885
US-20250361236-A9 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK EPHX1 1840/4885CARM1 2598/4885PRMT6 1544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.